Immunotherapy Research Articles & Analysis
20 news found
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. ...
“Over the past few years, we have been collaborating closely with research institutions and biopharmaceutical companies, aiming to stand at the forefront of scientific advancements and dedicated to addressing global health challenges through groundbreaking vaccine ...
Targeting these tumors with novel cellular immunotherapies will help address the unmet need for new treatment options for ovarian cancer patients. ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. ...
She brings decades of global experience in clinical research and development, commercialization, patient engagement, and regulatory strategy. ...
Immunotherapy, using therapies to ramp up a patient’s own immune system to fight cancer has been very successful in the treatment of melanoma and lung cancer. Checkpoint inhibitor therapy, a type of immunotherapy, is now being researched for GBM. Immunotherapies are designed to restore the body’s own complex immune ...
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach ...
Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Oce for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine ...
Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine ...
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence that had the mechanism of overcoming tolerance GI Innovation revealed KEYNOTE-B59’s clinical research process of ...
Daniel Olive, M.D., Ph.D., head of the immunity and cancer lab, Cancer Research Center of Marseille; professor, immunology and director, oncology research programs, Aix Marseille University; scientific founder and chairman of the board, ImCheck Therapeutics Prof. ...
Louis-Philippe Vézina, CEO of Angany Inc. and Douglas Hein, President of Lincoln Diagnostics Inc. announce the commitment of their respective companies to collaborate on Angany’s outreach to US allergists. A formal agreement to this effect was signed earlier this year. Angany introduces a new approach to allergy immunotherapy based on translational science and designed to overcome ...
With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and kill tumor cells. Up to now, two OV drugs have been marketed globally, and many more are still in the research and ...
There is a growing body of evidence that supports TTFields’ broad applicability with certain other cancer therapies, including radiation therapy, certain chemotherapies and certain immunotherapies. In clinical research and commercial experience to date, TTFields has exhibited no systemic toxicity, with mild to moderate skin irritation being the most common ...
Ramy joins from the Parker Institute for Cancer Immunotherapy where he was Chief Medical Officer and will remain on the board. ...
Bybit.bio
Moreover, the extensive experience of our management team with the research and clinical development of T cell immunotherapies will be extremely beneficial as we look to initiate clinical trials for ...
Biosceptre (Aust) P/L has today announced an agreement with The University of Sydney and Children’s Medical Research Institute (CMRI) to establish a new research program on CAR-T cell immunotherapy, at CMRI’s premises in Westmead, Western Sydney. ...
Calviri, Inc., a start-up focused on ending deaths from cancer through unconventional approaches to diagnostics and vaccines, was recently awarded a $300,000 Phase I grant through the Small Business Innovation Research Program (SBIR) at the National Cancer Institute (NCI). This one-year grant will support the development of a new test for establishing whether a cancer ...
ByCalviri
These findings promote new disease interception capability for the detection of early stage lung cancer and assessment of personalized immunotherapy efficacy in lung cancer. Previous research has demonstrated that the LuCED lung test, a non-invasive liquid biopsy sputum assay, has potential to address critical unmet medical needs to advance the lung cancer ...
Osivax develops a clinical-stage pipeline of vaccines and immunotherapies based on the oligoDOM® technology. oligoDOM® is a pro-immunogenic antigen reengineering technology which has been developed over the last 15 years by Imaxio. ...